Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Cash & Equivalents (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Cash & Equivalents for 16 consecutive years, with $10.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 57.67% to $10.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.4 million, a 57.67% increase, with the full-year FY2024 number at $6.2 million, up 8.47% from a year prior.
  • Cash & Equivalents was $10.4 million for Q3 2025 at Xtant Medical Holdings, up from $6.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $20.3 million in Q2 2021 to a low of $4.1 million in Q2 2023.
  • A 5-year average of $11.3 million and a median of $8.7 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 679.28% in 2021, then crashed 74.91% in 2023.
  • Xtant Medical Holdings' Cash & Equivalents stood at $18.2 million in 2021, then increased by 11.26% to $20.3 million in 2022, then plummeted by 71.84% to $5.7 million in 2023, then increased by 8.47% to $6.2 million in 2024, then surged by 67.77% to $10.4 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Cash & Equivalents are $10.4 million (Q3 2025), $6.9 million (Q2 2025), and $5.0 million (Q1 2025).